Experience of using secukinumab in the treatmentof patients with psoriasis
https://doi.org/10.51793/OS.2021.24.10.007
Abstract
Psoriasis is one of the most common chronic dermatoses. In recent years, there has been an increase in the number of patients with severe, disabling forms of dermatosis, resistant to the therapy. The disease significantly reduces the quality of life, disrupts patients' ability to work, which defines dermatosis as socially significant and entails the need to improve therapeutic approaches. Psoriatic arthritis, or artopathic psoriasis, is a chronic inflammatory disease of the joints, spine and enthesis, which can be observed in patients with psoriasis. The article presents the main current information about the pathogenesis of psoriasis and psoriatic arthritis with an emphasis on the immunopathological aspects of the development of diseases and the rationality for the use of the proinflammatory cytokine inhibitor interleukin-17 in the therapy. Modern advances in understanding the mechanism of development of psoriasis and psoriatic arthritis served as a rationale for the creation of a group of innovative targeted drugs – genetically engineered biological drugs, the mechanism of action of which is to block certain cytokines, both circulating in the systemic circulation and located in the inflamed tissue of psoriatic plaques or joint. In the article brief information about the results of clinical trials of secukinumab is provided; clinical examples highlight experience of effective treatment of patients with psoriasis and psoriatic arthritis. It has been shown that early cessation of the progression of the inflammatory process in psoriasis through biological therapy with secukinumab leads to a decrease in skin symptoms, a decrease in pain and subclinical inflammation in the joints. The high efficacy and safety of the drug allows complete control of the disease and improve the quality of life in patients.
About the Authors
N. V. Zilberberg
Ural Research Institute of Dermatology, Venereology and Immunopathology
Russian Federation
Russian Federation
Nataliya V. Zilberberg, Dr. of Sci. (Med.), Professor; Deputy Director for Research
8 Shcherbakova str., Yekaterinburg, 620076
Ya. V. Kascheeva
Ural Research Institute of Dermatology, Venereology and Immunopathology
Russian Federation
Russian Federation
Yana V. Kascheeva, MD; Head of the Department of Dermatovenereology
8 Shcherbakova str., Yekaterinburg, 620076
M. M. Kokhan
Ural Research Institute of Dermatology, Venereology and Immunopathology
Russian Federation
Russian Federation
Muza M. Kokhan, Dr. of Sci. (Med.), Professor; Head of the Scientific Clinical Department of Dermatology
8 Shcherbakova str., Yekaterinburg, 620076
References
1. Potekayev N. N., Kruglova L. S. Psoriatic disease. M.: MDV, 2014. Р. 264.
2. Global report on psoriasis. WHO 2016. Retrieved from WHO website: http://apps.who.int/iris/bitstream/10665/204417/1/9789241565189_eng.pdf.
3. Bakulev A. L. Psoriasis: clinical features, risk factors and associated comorbid states // Klin. farmakol. ter. 2019; 28 (1): 35-39.
4. Olisova O. Yu., Garanyan L. G. Epidemiology, etiopathogenesis and comorbidity in psoriasis – new facts // Rossiyskiy zhurnal kozhnykh i venericheskikh bolezney. 2017; 20 (4): 214-219.
5. Chiricozzi A., Romanelli P., Volpe E., Borsellino G., Romanelli M. Scanning the Immunopathogenesis of Psoriasis // Int. J. Mol. Sci. 2018; 19: 179. DOI: 10.3390/ijms19010179. Доступно: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5796128/pdf/ijms-19-00179.pdf.
6. Mahil S. K. Capon F., Barker J. N. Update on psoriasis immunopathogenesis and targeted immunotherapy // Semin. Immunopathol. 2016; 38: 11-27.
7. Coates L. C., Helliwell P. S. Psoriatic arthritis: state of the art review // Clin Med (Lond). 2017; 17 (1): 65-70.
8. Korotayeva T. V., Korsakova Yu. L. Psoriatic arthritis: classification, clinical picture, diagnosis, treatment // Nauchno-prakticheskaya revmatologiya. 2018; 56 (1): 60-69.
9. Alinaghi F., Calov M., Kristensen L. E. et al. Prevalence of psoriatic arthritis in patients with psoriasis: A systematic review and meta-analysis of observational and clinical studies // J Am Acad Dermatol. 2019; 80 (1): 251-265.
10. Christophers E. Comorbidities in psoriasis // J Eur Acad Dermatol Venerol. 2006; 20 (2): 52-55.
11. Boehncke W. H., Boehncke S. G. Cardiovascular morbidity in psoriasis: epidemiology, pathomechanisms, and clinical consequences // Ital Dermatol Venereol. 2008; 143 (5): 307-313.
12. Kimhi O., Caspi D., Borstein N. et al. Prevalence and risk factors of atherosclerosis in patients with psoriatic arthritis // Ann. Rheum Dis. 2006; 65 (11): 214-219.
13. Takeshita J., Grewal S., Langan S. M., Mehta N. N., Ogdie A. Psoriasis and comorbid diseases. Epidemiology // J Am Acad Dermatol. 2017; 76: 377-390.
14. Kruglova L. S., Khotko A. A., Koroleva M. A. Biological therapy and immunogenicity: IL-17 blocker – as a representative of a new class of target therapy for psoriasis // Gospital'naya meditsina: nauka i praktika. 2018: 1 (1); 14-22.
15. Nasonov Ye. L. New possibilities of pharmacotherapy of immunoinflammatory rheumatic diseases: focus on inhibitors of interleukin 17 // Nauchno-prakticheskaya revmatologiya. 2017; 55 (1): 68-86.
16. Deodhar A., Mease P. J., McInnes I. B., Baraliakos X., Reich K. et al. Long-term safety of secukinumab in patients with moderate-to-severe plaque psoriasis, psoriatic arthritis, and ankylosingspondylitis: integrated pooled clinical trial and post-marketing surveillance data // Arthritis Research & Therapy. 2019; 21 (111): 2-11.
17. Baraliakos X., Coates L. C., Gossec L., et al. Secukinumab improves axial manifestations in patients with psoriatic arthritis and inadequate response to NSAIDS: primary analysis of the MAXIMISE trial // Ann Rheum Dis. 2019; 78: 195-196.
18. McInnes I. B., Behrens F., Mease P. J. et al. Secukinumab versus adalimumab for treatment of active psoriatic arthritis (EXCEED): a double-blind, parallel-group, randomised, active-controlled, phase 3b trial // Lancet. 2020; 9 (395): 1496-1505.
19. Bagel J., Blauvelt A., Nia J., Hashim P., Patekar M. Secukinumab maintains superiority over ustekinumab in clearing skin and improving quality of life in patients with moderate to severe plaque psoriasis: 52-week results from a double-blind phase 3b trial (CLARITY) // JEADV. 2021; 35: 135-142.
20. Kungurov N. V., Keniksfest Y. V., Kokhan M. M., Syrneva N. A., Grishaeva E. V. Experience of using secukinumab in treatment of severe refractory psoriasis: a clinical case // Russian Open Medical Journal. 2019; 8 (2): 1-5.
21. Khismatullina Z. R., Yulamanov A. S. The drug secukinumab in the treatment of moderate resistant psoriasis: application experience // Kremlevskaya meditsina. Klinicheskiy vestnik, 2019; 1: 129-132.
Review
For citations:
Zilberberg N.V., Kascheeva Ya.V., Kokhan M.M. Experience of using secukinumab in the treatmentof patients with psoriasis. Lechaschi Vrach. 2021;(10):41-45. (In Russ.) https://doi.org/10.51793/OS.2021.24.10.007
Views:
326
JATS XML
Email this article 
